Verici Dx Plc
LSE:VRCI

Watchlist Manager
Verici Dx Plc Logo
Verici Dx Plc
LSE:VRCI
Watchlist
Price: 0.71 GBX -2.07%
Market Cap: £10.7m

Relative Value

The Relative Value of one VRCI stock under the Base Case scenario is hidden GBX. Compared to the current market price of 0.71 GBX, Verici Dx Plc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VRCI Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

VRCI Competitors Multiples
Verici Dx Plc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Verici Dx Plc
LSE:VRCI
11m GBP 7.6 -1.9 -2.6 -2.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 746 422.5 -160 391.7 -165 649.1 -163 758.9
US
Abbvie Inc
NYSE:ABBV
392.6B USD 6.6 167.8 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
187.9B USD 5.2 26.9 19.2 19.2
US
Gilead Sciences Inc
NASDAQ:GILD
171.1B USD 6 21.4 14.5 14.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.1B USD 10.4 33.2 24.4 25.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 087.6 -532.7 -682 -663.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.5B USD 5.7 17.7 16.9 19.2
AU
CSL Ltd
ASX:CSL
88.6B AUD 3.9 20.2 9.2 11.5
NL
argenx SE
XBRU:ARGX
43.4B EUR 14.2 33.4 67.6 69.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.6B USD 14.9 1 098.9 148.1 179.6
P/S Multiple
Revenue Growth P/S to Growth
US
Verici Dx Plc
LSE:VRCI
Average P/S: 3 068 053.1
7.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 746 422.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.2
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
6
4%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.4
10%
1
US
E
Epizyme Inc
F:EPE
2 087.6
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
0.9
AU
CSL Ltd
ASX:CSL
3.9
5%
0.8
NL
argenx SE
XBRU:ARGX
14.2
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.9
47%
0.3
P/E Multiple
Earnings Growth PEG
US
Verici Dx Plc
LSE:VRCI
Average P/E: 177.4
Negative Multiple: -1.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 391.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
167.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
26.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
21.4
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
33.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
10%
1.8
AU
CSL Ltd
ASX:CSL
20.2
11%
1.8
NL
argenx SE
XBRU:ARGX
33.4
42%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 098.9
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Verici Dx Plc
LSE:VRCI
Average EV/EBITDA: 39.5
Negative Multiple: -2.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 649.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
19.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.5
7%
2.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -682 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
11%
1.5
AU
CSL Ltd
ASX:CSL
9.2
8%
1.2
NL
argenx SE
XBRU:ARGX
67.6
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
148.1
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Verici Dx Plc
LSE:VRCI
Average EV/EBIT: 45.3
Negative Multiple: -2.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -163 758.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
19.2
20%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.5
13%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -663.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.2
13%
1.5
AU
CSL Ltd
ASX:CSL
11.5
11%
1
NL
argenx SE
XBRU:ARGX
69.5
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
179.6
N/A N/A